Testing a new immune cell therapy for difficult-to-treat blood cancers

Plain-English translation of NCT05768529 on ClinicalTrials.gov ↗ · Source last updated September 2023 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This study is testing a new treatment called Injection for people with a type of blood cancer called B-cell non-Hodgkin's lymphoma that has either come back after treatment or did not respond to previous treatments. is an immune therapy designed to help your body's immune system fight cancer cells. The trial will assess whether this medication is safe and whether it works to help people with this difficult-to-treat cancer.

When non-Hodgkin's lymphoma comes back or doesn't respond to standard treatments, patients have very limited options and face a serious situation. This study exists to find out whether this new immune-based treatment can help patients whose cancer has proven resistant to conventional therapies.

Do you qualify?

You likely qualify if…

you are between 18 and 70 years old
you have been diagnosed with a specific type of B-cell non-Hodgkin's lymphoma (such as diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, or high-grade B-cell lymphoma)
your cancer has come back or has not responded to at least two previous lines of treatment, including standard chemotherapy and CD20-targeted drugs
you have at least one measurable tumor lesion that can be tracked on imaging
your bone marrow, liver, kidney, and lung function are adequate enough to tolerate the treatment
you are in good enough general health (Eastern Cooperative Oncology Group performance status 0 or 1)

You likely don't qualify if…

you are pregnant or breastfeeding, or unwilling to use effective contraception during and for at least one year after the treatment
you have severely compromised bone marrow function, with very low blood cell counts
you have significant liver, kidney, or lung disease beyond what the trial allows
your cancer cells do not express the CD20 protein (which is required for this treatment to work)

What participation looks like

If you join this trial, you will first receive chemotherapy drugs (fludarabine and cyclophosphamide) over several days to prepare your body for the treatment. A few days later, you will receive an infusion of intravenously. Throughout the study, you will have regular visits for blood tests, imaging scans, and physical exams to monitor how well the treatment is working and to watch for any side effects. The trial is designed for 100 patients and is currently recruiting participants.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Trial locations(2 sites)

China

The Third Xiangya Hospital of Central South University, Changsha, Hunan

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu